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Sir Peter Lachmann was an exceptional and gifted scientist whose intellectual contri-
butions to biomedical science have been immense. He was an inspirational leader whose
scientific and intellectual influence was wide ranging, influential, and went far beyond his
field. He was one of the most outstanding immunologists of the last 50 years.
His major scientific discoveries were in the field of complement. In both the innate
and adaptive immune response, the complement system plays a key role in host defence
against viral, bacterial, fungal, and protozoan pathogens. The complement system is a
complex and highly regulated molecular system under exquisite homeostatic control to
prevent untoward activation and immunopathology. Through his understanding of the
alternative pathway of complement, he elucidated the key role that the third component of
complement, C3, and its breakdown fragments played in the early stages of complement
activation. His C3 ‘tickover hypothesis’ and the details of the C3b feedback loop proved
seminal to understanding the activation and dysregulation of the complement system in
inflammatory pathways. This led to the molecular understanding of the key components
of both the classical and alternative pathways of complement activation and their role in
virus immunity immunopathology.
Peter’s research career of some 50+ years spanned both the fundamental and clinical
aspects of immunology, leading to the publication of more than 450 research papers in
top journals. His discoveries were at the cutting edge of immunology. His publications
included important discoveries on complement inhibitors, complement genetics, and the
genetic deficiencies in human complement that predispose to life-threatening infections.
Through the study of complement polymorphisms, his research group and that of his many
colleagues defined the genetic linkages between the different complement proteins. This
has led to a clearer understanding of the inherited deficiencies of the terminal components
of the human complement system in recurrent infections. The recent emergence of the dual
role of C3 of the complement system both in coronavirus immunity and the inflammatory
cascades in severe coronavirus infections illustrates the central role that the complement
system plays in viral infections caused by SARS-CoV, MERS-CoV, and SARS-CoV 2. In
due course, the rational design of complement inhibitors based on research leads coming
from Peter’s complement research will offer new approaches to controlling the severity of
coronavirus diseases. In this context, Sir Peter Lachmann was a biomedical scientist ahead
of his time.
He had a distinctive lecturing style that was memorable and often enlivened scientific
meetings. I recall him delivering an immunology lecture on our advanced course in
immunology at the Postgraduate Medical School at the Hammersmith Hospital in London
on Theories of Antibody Formation. To generate the vast range of antibody and T cell
specificities required to deal with the universe of antigens, it had been hypothesised that
the immune system required a generator of diversity (GOD). Peter’s view was that as T and
B lymphocytes both recognise antigen that there is either one GOD for both cell types—a
monotheistic argument, or one for T cells and one for B cells—a ditheistic argument. At that
time (1975), the molecular nature of the T and B cell receptors was unresolved, and Peter’s
conclusion was that, in his view, he tended towards ‘an agnostic ditheism’.
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He was elected Fellow of the Royal Society in 1996 and received many academic
accolades including the Gold Medal of the European Complement Network in 1997. He
was knighted for service to medical science in 2002.
He has been a huge and constant part of hundreds of scientific lives and careers in
science and medicine, including my own. His critical insights and influence have had
a wide impact both nationally and internationally. He was always very supportive of
younger generations of research scientists. There are many basic and clinical scientists in
senior academic positions across the globe who were privileged to have worked with Peter
and to have had the support of such a brilliant scientific mind.
Sir Peter was an inspirational leader whose scientific and intellectual influence was
colossal and went far beyond his field. He had global stature in biomedical sciences
through his research, education, and mentoring of the next generation of scientists. In
1998, he became the founding President of the Academy of Medical Sciences, now the
foremost academy of medical sciences in the UK. The Academy has proven to be a much-
needed academy. Without his foresight and intellectual drive, the academy would not have
come into existence. Currently, the Academy of Medical Sciences broadly impacts the UK
biomedical science developments of benefit to Government policies and many research
organisations. His critical insights, influence, and wise counsel were always sought after
and held in high esteem by many in the scientific community and the pharmaceutical
industry. He was President of the Royal College of Pathologists and Vice President and
Biological Secretary of the Royal Society. His many roles involved him in ethical and policy
controversies in medical and biological science. He was a Fellow of Christ’s College and
Honorary Fellow of Trinity College.
I first met Peter when I was a graduate student in 1967 in the laboratory of Professor
RRA Coombs, FRS, who had developed the Coombs Test for haemolytic disease of the
newborn. Robin Coombs was also the PhD supervisor of Peter. I had modified a sensitive
haemolytic plaque assay for the detection of complement by single cells using red cells
prepared by Peter and coated with complement components C5, 6, and 7, known as EC567
cells. By incorporating C9 in the plaquing medium, any tissue cells which secreted C8
were detected as plaque-forming cells. Peter told me to be in the lab at 8 a.m. when he had
prepared the EC567, and I prepared the cell populations. By midmorning, C8 PFC were
detected in the spleen and liver, and I rushed to show Peter the results. Peter was nowhere
to be seen. By 6 p.m., he finally reappeared; I asked him where he had been, to which
he replied, in his characteristic challenging style, ‘Surely you knew (one of his favourite
remarks which always challenged ones knowledge), that when the temperature in the
Cambridge falls below freezing for 4 consecutive days in the winter the University declares
it a skating holiday! I have been skating in the Fens. It is a well known University Statute—
you should look it up in Statutes and Ordinances of the University’. Such was his wonderful
encyclopaedic memory and love of obscure facts—he was, however, very interested in my
results, thus began a lifetime of knowing and working with Peter (Figure 1).
Viruses 2021, 13, x FOR PEER REVIEW 2 of 3 
 
 
At that time (1975), the molecular nature of the T and B cell receptors was unresolved, and 
Peter’s conclusion was that, in his view, he tended towards ‘an agnostic ditheism’.  
He was elected Fellow of the Royal Society in 1996 and received many academic 
accolades including the Gold Medal of the European Complement Network in 1997. He 
was knighted for service to medical science in 2002. 
He has been a huge and constant part of hundreds of scientific lives and careers in 
science and medicine, including my own. His critical insights and influence have had a 
wide impact both nationally and internationally. He was always very supportive of 
younger generations of research scientists. There are many basic and clinical scientists in 
senior academic positions across the globe who were privileged to have worked with 
Peter and to have had the support of such a brilliant scientific mind. 
Sir Peter was an inspirational leader whose scientific and intellectual influence was 
colossal and went far beyond his field. He had global stature in biomedical sciences 
through his research, education, and mentoring of the next generation of scientists. In 
1998, he became the founding President of the Academy of Medical Sciences, now the 
foremost academy of medical sciences in the UK. The Academy has proven to be a much-
needed academy. Without his foresight and intellectual drive, the academy would not 
have come into existence. Currently, the Academy of Medical Sciences broadly impacts 
the UK biomedical science developments of benefit to Government policies and many 
research organisations. His critical insights, influence, and wise counsel were always 
sought after and held in high esteem by many in the scientific community and the 
pharmaceutical industry. He was President of the Royal College of Pathologists and Vice 
President and Biological Secretary of the Royal Society. His many roles involved him in 
ethical and policy controversies in medical and biological science. He was a Fellow of 
Christ’s College and Honorary Fellow of Trinity College. 
I first met Peter when I was a graduate student in 1967 in the laboratory of Professor 
RRA Coombs, FRS, who had developed the Coombs Test for haemolytic disease of the 
newborn. Robin Coombs was also the PhD supervisor of Peter. I had modified a sensitive 
haemolytic plaque assay for the detection of complement by single cells using red cells 
prepared by Peter and coated with complement components C5, 6, and 7, known as EC567 
cells. By incorporating C9 in the plaquing medium, any tissue cells which secreted C8 
were detected as plaque-forming cells. Peter tol  me to be in the lab at 8 a.m. when he had 
prepar d the EC567, and I prepar d th  cell populations. By midmorning, C8 PFC were 
detected in the spleen and liv r, nd I rush d t  show Peter the results. Peter was nowh  
to be seen. By 6 .m., he finally reappeared; I a ked him where he had been, to whic  h  
replied, i  his characteristic chall nging style, ‘Surely you kn w (one of his favourite 
remarks whic  alw ys challenged o es know dge), that whe  the temperature in th  
Cambridge falls below freezing for 4 co secutiv  days in the winter the University 
declares it a skating holiday! I have been ska ng in the Fens. It is a w ll known University 
St tute—you should look it up in Statutes and Ordinances of the University’. Such was 
his wonderful encyclopaedic memory a d love of obscure facts—he was, however, very 
i terested in my results, thus b gan a lifetime of knowing and working w th P ter (Figure 
1).  
 
Figure 1. Sir Peter J. Lachmann—a quite rare photo of a laughing Peter. i r . ir t r J. it r r t f l i t r.
Sir Peter was loyal, generous, and supportive to many of his colleagues across the
world and leaves a huge legacy. He will be much missed. Our sympathies are with his
wife Sylvia and his family. Sylvia was a huge support to Peter and his family. Both Peter
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and Sylvia hosted many splendid occasions in his lovely house in Cambridge. Visiting
scientists who came to Cambridge to work with Peter in his laboratory could always be
assured of a warm and intellectually stimulating time.
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